Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHN-010
- Development stage
- Phase 1
- Lead developer
- Pheon Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PHN-010 is a novel antibody-drug conjugate (ADC) developed by Pheon Therapeutics for the treatment of advanced solid tumors. The drug consists of a monoclonal antibody linked to a topoisomerase I inhibitor payload via a stable hydrophilic linker with a drug-to-antibody ratio (DAR) of 8. It is designed to deliver the cytotoxic agent directly to cancer cells, thereby increasing specificity and reducing off-target toxicity compared to traditional chemotherapies. PHN-010 is currently being evaluated in first-in-human Phase 1 clinical trials for patients with various advanced or metastatic solid tumors, including colorectal adenocarcinoma, epithelial ovarian cancer, endometrial cancer, cervical carcinoma, and non-small cell lung cancer. The route of administration is intravenous infusion[1][2][3][4][5][7].
- Other names
- PHN 010PHN010PHN-010
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on PHN-010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PHN-010.